- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Auras.
Displaying page 1 of 1.
| EudraCT Number: 2011-006207-36 | Sponsor Protocol Number: 19122011 | Start Date*: 2012-09-27 |
| Sponsor Name:Proreo Pharma Innovation AG | ||
| Full Title: A multi centre, double blind, randomised, placebo controlled crossover study to evaluate the efficacy and tolerability of picotamide in the prophylaxis of migraine in patients presenting with migra... | ||
| Medical condition: Migraine with aura, ICD-10NA G43.1 | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-000897-21 | Sponsor Protocol Number: N01280 | Start Date*: 2008-02-05 | |||||||||||
| Sponsor Name:UCB, Inc. | |||||||||||||
| Full Title: A multi-center, double-blind, historical control, randomized conversion to monotherapy study with Keppra XR for treatment of partial onset seizures | |||||||||||||
| Medical condition: partial onset seizures | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-013701-34 | Sponsor Protocol Number: VMMET009 | Start Date*: 2011-09-01 | |||||||||||
| Sponsor Name:Hospital of the University of Munich | |||||||||||||
| Full Title: Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo- controlled trial | |||||||||||||
| Medical condition: vestibular migraine | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001288-18 | Sponsor Protocol Number: 16-API-01 | Start Date*: 2019-01-08 | |||||||||||
| Sponsor Name:CHU de Nice | |||||||||||||
| Full Title: ASIC channels and migraine disorders - Proof of concept study on the efficacy of Amiloride in prophylaxis of Migraine with Aura - APAM study | |||||||||||||
| Medical condition: Migraine with aura | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-000144-14 | Sponsor Protocol Number: N01276 | Start Date*: 2008-07-14 | |||||||||||
| Sponsor Name:UCB Inc | |||||||||||||
| Full Title: An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to... | |||||||||||||
| Medical condition: Partial onset seizures with or without secondary generalization. | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-010721-39 | Sponsor Protocol Number: NXN-188-202 | Start Date*: 2009-04-27 | |||||||||||
| Sponsor Name:Peer Tfelt-Hansen | |||||||||||||
| Full Title: A phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks with Aura | |||||||||||||
| Medical condition: MIgraine with aura | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-000145-58 | Sponsor Protocol Number: N01306 | Start Date*: 2008-07-11 | |||||||||||
| Sponsor Name:UCB Pharma S.A. | |||||||||||||
| Full Title: An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to... | |||||||||||||
| Medical condition: Partial onset seizures with or without secondary generalization. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) ES (Completed) HU (Prematurely Ended) FI (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005689-40 | Sponsor Protocol Number: COL-MIG-302 | Start Date*: 2016-10-18 | |||||||||||||||||||||||||||||||
| Sponsor Name:CoLucid Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
| Full Title: A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A randomized, double-blind, placebo-controlled parallel group study (SPARTAN) | |||||||||||||||||||||||||||||||||
| Medical condition: acute migraine | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-002470-27 | Sponsor Protocol Number: 3101-312-002 | Start Date*: 2021-05-12 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Allergan Limited | ||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE 3, MULTICENTER, OPEN-LABEL 52-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODI... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) HU (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-005239-22 | Sponsor Protocol Number: BHV3000-404 | Start Date*: 2022-06-20 | |||||||||||||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||||||||||||
| Full Title: A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens | |||||||||||||||||||||||
| Medical condition: Acute Migraine (with or without aura) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) AT (Completed) FR (Completed) SE (Completed) IT (Completed) PL (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2021-005246-15 | Sponsor Protocol Number: BHV3000-315 | Start Date*: 2022-08-23 | |||||||||||||||||||||
| Sponsor Name:Biohaven Pharmaceuticals Holding Company Limited | |||||||||||||||||||||||
| Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age | |||||||||||||||||||||||
| Medical condition: Acute Migraine (with or without aura) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2015-005674-37 | Sponsor Protocol Number: COL-MIG-305(H8H-CD-LAHL) | Start Date*: 2016-11-01 | |||||||||||||||||||||||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||||||||||||||||||||||
| Full Title: An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR) | |||||||||||||||||||||||||||||||||
| Medical condition: acute migraine | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-003761-18 | Sponsor Protocol Number: BHV3000-312 | Start Date*: 2022-01-20 | |||||||||||||||||||||||||||||||
| Sponsor Name:Biohaven Pharmaceuticals Inc. | |||||||||||||||||||||||||||||||||
| Full Title: Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < ... | |||||||||||||||||||||||||||||||||
| Medical condition: Acute Migraine (with or without aura) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) PL (Trial now transitioned) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-003517-35 | Sponsor Protocol Number: BHV3000-311 | Start Date*: 2021-05-05 | |||||||||||||||||||||||||||||||
| Sponsor Name:Pfizer, Inc. | |||||||||||||||||||||||||||||||||
| Full Title: Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in childr... | |||||||||||||||||||||||||||||||||
| Medical condition: Acute Migraine (with or without aura) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: SE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
